We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.41B
AUM Growth
-$2.89B
Cap. Flow
-$1.47B
Cap. Flow %
-27.24%
Top 10 Hldgs %
37.29%
Holding
165
New
19
Increased
15
Reduced
46
Closed
34

Top Buys

Rank Stock Value
1
LOGC
LogicBio Therapeutics, Inc. Common Stock
LOGC
+$78.1M
2
THOR
Synthorx, Inc. Common Stock
THOR
+$77.1M
3
CVS icon
CVS Health
CVS
+$59.3M
4
CELG
Celgene Corp
CELG
+$58.5M
5
GH icon
Guardant Health
GH
+$56.5M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$149M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$98.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$81.7M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81M
5
EW icon
Edwards Lifesciences
EW
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Financials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGTX icon
101
MeiraGTx Holdings
MGTX
$1.07B
$4.53M 0.08%
469,953
+216,770
+86% +$2.73M
XFOR icon
102
X4 Pharmaceuticals
XFOR
$371M
$4.34M 0.08%
10,383
– –
APLS
103
DELISTED
Apellis Pharmaceuticals
APLS
$4.31M 0.08%
+327,000
New +$5.02M
RNAC icon
104
Cartesian Therapeutics
RNAC
$216M
$4.2M 0.08%
52,635
-3,792
-7% -$865K
TECX
105
Tectonic Therapeutic
TECX
$531M
$4.16M 0.08%
20,825
-8
-0% -$2.44K
ELDN icon
106
Eledon Pharmaceuticals
ELDN
$259M
$4.06M 0.08%
140,951
– –
XENE icon
107
Xenon Pharmaceuticals
XENE
$6.16B
$4.01M 0.07%
634,812
– –
CTIC
108
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.67M 0.07%
5,000,000
– –
SAGE
109
DELISTED
Sage Therapeutics
SAGE
$3.48M 0.06%
+36,300
New +$4.15M
CNST
110
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$3.35M 0.06%
835,842
– –
FOLD
111
DELISTED
Amicus Therapeutics
FOLD
$3.09M 0.06%
323,009
-1,440,268
-82% -$15.8M
YI
112
111 Inc
YI
$33.4M
$3.07M 0.06%
50,000
– –
VTAK icon
113
Catheter Precision
VTAK
$1.01M
$2.78M 0.05%
1
– –
ECOR icon
114
electroCore
ECOR
$51.3M
$2.49M 0.05%
26,548
– –
RLM
115
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
$1.89M 0.03%
1,021,484
– –
MRNS
116
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.43M 0.03%
124,525
-17,375
-12% -$352K
IMMU
117
CALL
DELISTED
Immunomedics Inc
IMMU
$1.43M 0.03%
+100,000
New +$1.99M
AMRN
118
Amarin Corp
AMRN
$297M
$1.1M 0.02%
+4,050
New +$1.48M
MDCO
119
DELISTED
Medicines Co
MDCO
$1.04M 0.02%
+54,600
New +$1.27M
AFMD
120
DELISTED
Affimed
AFMD
$1.02M 0.02%
32,665
– –
SNDX icon
121
Syndax Pharmaceuticals
SNDX
$1.68B
$943K 0.02%
212,000
-225,000
-51% -$1.23M
ADMS
122
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
$854K 0.02%
+100,000
New +$1.3M
SCTL
123
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$762K 0.01%
119,703
– –
SRRA
124
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$551K 0.01%
10,428
-8,750
-46% -$559K
BLRX
125
BioLineRX
BLRX
$12.3M
$454K 0.01%
1,731
– –
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2018 Portfolio in Review

As of Q4 2018, OrbiMed held 165 positions worth $5.41B, down 35% from $8.3B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $1.47B in Q4 2018, closing 34 positions and reducing 46 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in LogicBio Therapeutics, Inc. Common Stock worth $67.3M.

  • OrbiMed's largest Q4 2018 buy was LogicBio Therapeutics, Inc. Common Stock: 6,466,783 shares worth $67.3M.
  • OrbiMed added most to Celgene Corp in Q4 2018, an estimated $58.5M increase.
  • OrbiMed's biggest Q4 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $98.5M.
  • OrbiMed fully exited Jazz Pharmaceuticals in Q4 2018, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 37% of its $5.41B portfolio in Q4 2018.
  • OrbiMed opened 19 new positions and closed 34 in Q4 2018.
  • OrbiMed's portfolio value fell 35% quarter-over-quarter to $5.41B.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.